GRAIL Inc Share Price Today: Live Updates & Key Insights

GRAIL Inc share price today is $44.12, up -4.3%. The stock opened at $45 against the previous close of $46.33, with an intraday high of $45.835 and low of $43.695.

GRAIL Inc Share Price Chart

GRAIL Inc

us-stock
To Invest in {{usstockname}}
us-stock

GRAIL Inc Share Price Performance

$44.12 -0.043(-4.3%) GRAL at 13 Mar 2026 01:22 PM Diagnostics & Research
Lowest Today 43.695
Highest Today 45.835
Today’s Open 45
Prev. Close 46.33
52 Week High 118.84
52 Week Low 20.44
Day’s Range: Low 43.695 High 45.835
52-Week Range: Low 20.44 High 118.84
1 day return -
1 Week return -11.8
1 month return -54.55
3 month return -51.2
6 month return +12.58
1 year return +64.63
3 year return -
5 year return -
10 year return -

GRAIL Inc Institutional Holdings

GRAIL Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

GRAIL Inc Fundamentals

Market Cap 1868.55 M

PB Ratio 0.7615

PE Ratio 0.0

Enterprise Value 1018.98 M

Total Assets 2922.02 M

Volume 1056110

GRAIL Inc Company Financials

Annual Revenue FY25:147172000 147.2M, FY23:93105000 93.1M

Annual Profit FY25:73921000 73.9M, FY23:-95611000 -95.6M

Annual Net worth FY25:-408351000 -408.4M, FY23:-1283652000 -1283.7M

Quarterly Revenue Q3/2025:43597000 43.6M, Q2/2025:35544000 35.5M, Q1/2025:31837000 31.8M, Q3/2024:28652000 28.7M, Q2/2024:31970000 32.0M

Quarterly Profit Q3/2025:125358000 125.4M, Q2/2025:-17775000 -17.8M, Q1/2025:-19929000 -19.9M, Q3/2024:-22233000 -22.2M, Q2/2024:-17912000 -17.9M

Quarterly Net worth Q3/2025:-99176000 -99.2M, Q2/2025:-113985000 -114.0M, Q1/2025:-106213000 -106.2M, Q3/2024:-125688000 -125.7M, Q2/2024:-1585337000 -1585.3M

About GRAIL Inc & investment objective

Company Information GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Organisation Diagnostics & Research

Employees 1000

Industry Diagnostics & Research

CEO Mr. Robert P. Ragusa

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right